Safety and Effectiveness of NATRELLE® 410 Highly Cohesive, Anatomically Shaped, Silicone-filled X-Style and L-Style Breast Implants

Stopped early · Not applicable

Conditions studied: Breast Augmentation, Breast Reconstruction, Breast Implant Revision

In brief

This is a prospective, multicenter study of the safety and effectiveness of NATRELLE® 410 Highly Cohesive, Anatomically Shaped, Silicone-Filled X-Style and L-Style Breast Implants.

Key facts

Study ID

NCT01785069

Run by

Allergan

People needed

355

Starts

2012-12-10

Expected to finish

2015-11-30

Last updated by the study team

2020-06-25

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• For entry in this study, participants must have been enrolled in the 410 Continued Access (CA) Clinical Study or 410 Continued Access Reconstruction/Revision Expansion (CARE) Clinical Study under the inclusion criteria listed below and received NATRELLE® 410 Highly Cohesive, Anatomically Shaped, Silicone-Filled X-Styles or L-Styles breast implants
• Female, age 18 or older
• Present with 1 or more of the following conditions:
• Primary breast augmentation (i.e., no previous breast implant surgery) indicated for subject dissatisfaction with size or shape of breast (e.g., mammary hypoplasia), asymmetry, ptosis, or aplasia
• Primary breast reconstruction (i.e., no previous breast implant surgery other than implantation of tissue expanders or contralateral augmentation for asymmetry) indicated, in the affected breast, for mastectomy for cancer, prophylactic mastectomy, or breast trauma (resulting in mastectomy) and for the unaffected breast, contralateral asymmetry (may be performed on the date of the mastectomy or the date when the permanent implants are placed in the reconstructed breast)
• Breast implant revision surgery (i.e., removal and replacement of breast implants) indicated for previous augmentation or reconstruction with silicone-filled or saline-filled breast implants
• Has adequate tissue available to cover implants
• Willing to undergo magnetic resonance imaging (MRI) at the specified follow-up visits for subjects at MRI designated sites and be eligible for MRI (e.g., no implanted metal or metal devices, no history of severe claustrophobia)

You may not qualify if…

• For entry in this study, participants must have been enrolled in the 410 CA Clinical Study or 410 CARE Clinical Study, meeting the exclusion criteria listed below, did not receive any NATRELLE® 410 Highly Cohesive, Anatomically Shaped, Silicone-Filled FM, FF, MM, or MF Style Breast Implants, and have not undergone implant removal with or without replacement surgery
• Does not have advance fibrocystic disease considered to be premalignant without accompanying subcutaneous mastectomy
• Does not have existing carcinoma of the breast, without mastectomy
• Does not have abscess or infection in the body at the time of enrollment
• Is not pregnant or nursing
• Does not have any disease, including uncontrolled diabetes (e.g., hemoglobin A1c (HbA1c) > 8%), that is clinically known to impact wound healing ability
• Does not show tissue characteristics that are clinically incompatible with mammaplasty, such as tissue damage resulting from radiation inadequate tissue, compromised vascularity, or ulceration
• Does not have or is under treatment for any condition that may constitute an unwarranted surgical risk (e.g., unstable cardiac or pulmonary problems)
• Does not show psychological characteristics that may be incompatible with the surgical procedure and the prosthesis, such as inappropriate attitude or motivation (e.g., body dysmorphic disorder)
• Is not willing to undergo further surgery for revision, if medically required

Where it is running

• Laurence Berkowitz — Campbell, California, United States
• Roy Hong — Palo Alto, California, United States
• Eric Bachelor — Pleasanton, California, United States
• Gregory Liebscher — Colorado Springs, Colorado, United States
• Scott Spear — Washington D.C., District of Columbia, United States
• Calvin Peters — Orlando, Florida, United States
• Walter Erhardt — Albany, Georgia, United States
• James Namnoum — Atlanta, Georgia, United States
• Janet Turkle — Carmel, Indiana, United States
• Julene Samuels — Louisville, Kentucky, United States
• Timothy Mickel — Monroe, Louisiana, United States
• John Renucci — Grand Rapids, Michigan, United States
• Steven Morris — Midland, Michigan, United States
• Charles Nathan — Chesterfield, Missouri, United States
• Herluf Jr. Lund — Chesterfield, Missouri, United States
• Patricia McGuire — Creve Coeur, Missouri, United States
• Perry Johnson — Omaha, Nebraska, United States
• Peter Hyans — Berkeley Heights, New Jersey, United States
• Peter Hetzler — Little Silver, New Jersey, United States
• Caroline Glicksman — Sea Girt, New Jersey, United States
• Tracy Pfeifer — Great Neck, New York, United States
• Lloyd Gayle — New York, New York, United States
• Raymond Isakov — Cleveland, Ohio, United States
• Craig Colville — Toledo, Ohio, United States
• Frank Barone — Toledo, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.